Application of ethylmethylhydroxypyridine succinate in patients with the burns

Abstract

Objective. To determine clinical efficacy of the preparation ethylmethylhydroxypyridine succinate application in early period of the burn disease. Materials and methods. In 14 patients with burns ethylmethylhydroxypyridine succinate (the main group) was applied in complex treatment, while 22 patients were treated in accordance to standard scheme (control group). The content of TBK–active products, superoxide dismutase, tumor necrosis factor–α and S–nitrosothiols in peripheral blood on the 1–2, 7–8 and 13–14th days after the burn trauma were determined. Results. In the main group versus initial values there were registered: the content of TBK–active products lowered in 1.22 times, the content of SOD raised in 1.73 times, the content of the S–nitrosothiols lowering in 117 times, while content of the tumor necrosis factor–α versus certain index in control group reduced in 1.15 times on 7–8th day and in 1.08 times on the 13–14th day after the burn. In the main group of patients the average square of necrectomies have reduced, volume of performance of autodermoplasty was less in 1.12 times, in them less surgical interventions performed, and the stationary stay has been shortened in 1.48 times. Conclusion. Application of ethylmethylhydroxypyridine succinate promotes reduction of endothelial dysfunction, oxidative stress, inflammation, what improves the burns treatment results, reduces the surgical interventions quantity and the patients' stationary stay.